Absence of neuroinflammation in Grn+/− mice with FTD-related behavioral abnormalities. A, Representative images of Iba1 immunohistochemistry in the thalamus of control and progranulin-deficient mice. B–E, Quantification of Iba1 immunoreactivity in various brain regions (N = 6 mice per genotype; age = 12 months). B,
Grn−/−, but not Grn+/−, mice had microgliosis in thalamus (ANOVA, p < 0.0001; on post-hoc tests only Grn−/− mice differ from other groups, *** p < 0.0001). C,
Grn−/−, but not Grn+/−, mice had microgliosis in hippocampus (ANOVA, p < 0.005; on post-hoc tests only Grn−/− mice differ from other groups, ** p < 0.001). D,
Grn−/−, but not Grn+/−, mice had microgliosis in cortex (ANOVA, p < 0.0001; on post-hoc tests only Grn−/− mice differ from other groups, *** p < 0.0001). E, There were no significant differences in Iba1 immunoreactivity in amygdala. F–I, qPCR analysis of TNF-α mRNA levels in various brain regions (N = 5–6 mice per genotype; age = 19 months). F,
Grn−/−, but not Grn+/−, mice had increased TNF-α in thalamus (ANOVA, p < 0.005; on post-hoc tests only Grn−/− mice differ from other groups, ** p < 0.001). G, There were no significant differences in TNF-α in hippocampus. H,
Grn−/−, but not Grn+/−, mice had increased TNF-α in cortex (ANOVA, p < 0.05; on post-hoc tests only Grn−/− mice differ from other groups, * p < 0.05). I, Although trending, no significant differences in TNF-α in amygdala were detected (ANOVA, p = 0.12). J–M, Quantification of GFAP immunoreactivity in various brain regions (N = 6 mice per genotype; age = 12 months). J,
Grn−/−, but not Grn+/−, mice had astrocytosis in thalamus (ANOVA, p < 0.0001; on post-hoc tests only Grn−/− mice differ from other groups, *** p < 0.0001). K,
Grn−/−, but not Grn+/−, mice had astrocytosis in hippocampus (ANOVA, p = 0.0001; on post-hoc tests only Grn−/− mice differ from other groups, *** p < 0.001). L,
Grn−/−, but not Grn+/−, mice had astrocytosis in cortex (ANOVA, p < 0.0001; on post-hoc tests only Grn−/− mice differ from other groups, *** p < 0.0001). M, There were no significant differences in GFAP immunoreactivity in amygdala.